Evidence map›Paper›PMID 36932954›Full record

ArticleJournal of medicinal chemistry2023

BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α

Daniel Meibom, Jutta Meyer, Clemens-Jeremias von Buehler, Karl D Collins, Stefanie Maassen, Kersten Matthias Gericke, Jörg Hüser, Joachim Mittendorf, Nuria Ortega Hernandez, Jens Schamberger and 5 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daniel MeibomBayer AG, 42113 Wuppertal, Germany.ORCID 0000-0003-4978-9842
Jutta MeyerBayer AG, 42113 Wuppertal, Germany.
Clemens-Jeremias von BuehlerBayer AG, 42113 Wuppertal, Germany.
Karl D CollinsBayer AG, 42113 Wuppertal, Germany.
Stefanie MaassenBayer AG, 42113 Wuppertal, Germany.
Kersten Matthias GerickeBayer AG, 42113 Wuppertal, Germany.
Jörg HüserBayer AG, 42113 Wuppertal, Germany.
Joachim MittendorfBayer AG, 42113 Wuppertal, Germany.
Nuria Ortega HernandezBayer AG, 42113 Wuppertal, Germany.
Jens SchambergerBayer AG, 42113 Wuppertal, Germany.
Jan StampfussBayer AG, 42113 Wuppertal, Germany.
Alexander StraubBayer AG, 42113 Wuppertal, Germany.
Afra TorgeBayer AG, 42113 Wuppertal, Germany.
Norbert WitowskiBayer AG, 42113 Wuppertal, Germany.
Frank WunderBayer AG, 42113 Wuppertal, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After acute myocardial infarction, early reperfusion is the most effective strategy for reducing cardiac damage and improving clinical outcome. However, restoring blood flow to the ischemic myocardium can paradoxically induce injury by itself (reperfusion injury), with microvascular dysfunction being one contributing factor. α

Indexed as

Adrenergic AgentsAnimalsRatsAdrenergic Agents

Identifiers

PMID36932954
PMCPMC10108358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.